Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medigene AG
High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER
There are as many rare disease patients as there are diabetics, Cigna’s Steve Miller notes, arguing that exorbitant prices for each treatment could drive counterproductive categorical exclusions by payers.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Plus: Korean firms working on repurposed drug which showed far higher efficacy than remdesivir and chloroquine in pre-clinical tests
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- Trianta Immunotherapies GmbH
- Medigene Immunotherapies GmbH